Lupin Inks $ 50 Million Licensing Deal with Zentiva
.jpg)
Lupin Ltd, a major pharmaceutical company, has established a licensing and supply agreement for the commercialization of its biosimilar, Certolizumab Pegol, with the Zentiva Group, which includes potential milestone earnings of up to $ 50 million.
This partnership aims to enhance the availability of high-quality, affordable biosimilar Certolizumab Pegol for patients around the globe, according to a regulatory filing by Lupin.
By the agreement, Lupin will handle the development, manufacturing, and supply of the product within the specified regions.
Conversely, Zentiva, a pharmaceutical company operating across Europe, will manage commercialization efforts outside of the US and Canada, particularly in European and CIS markets, using its comprehensive commercial framework and regulatory knowledge, according to the company.
Lupin will take charge of commercialization in the remaining areas, including the US and Canada. "Both parties will invest in the development of the new biosimilar.
Also Read: 5 Pharma Leaders Trying to Prevent the Next Pandemic in India
Lupin will receive an upfront payment of USD 10 million following the execution of the agreement, along with potential total milestone payments for development and regulatory achievements reaching $ 50 million," stated the Indian pharmaceutical leader.
The profits from the designated markets will be divided between the two firms. Certolizumab Pegol is approved for treating patients with rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, non-radiographic axial spondyloarthritis, moderate-to-severe plaque psoriasis, and Crohn's disease.
Also Read: Homegrown Ice Cream Brands that Can Cool You Off the Sweltering Heat
“Our global development and commercialisation partnership with Zentiva, with its pan-European focus, enables Lupin to commercialise this unique biosimilar in its core markets and through Zentiva in Europe," Lupin President of Corporate Development Fabrice Egros says.